The iboga plant, scientifically known as Tabernanthe iboga, is a perennial shrub native to Central and West Africa. It grows primarily in regions such as Gabon, Cameroon, and the Republic of the Congo, thriving in tropical forest environments. From a botanical perspective, iboga belongs to the Apocynaceae family, which includes other alkaloid-producing plants studied in pharmacology …
Ibogaine is a naturally occurring psychoactive compound found in the root bark of the African shrub Tabernanthe iboga. The plant is native to Central and West Africa, where it has historically been used in ceremonial and cultural contexts. In modern science, ibogaine is studied for its complex interactions with the brain and nervous system rather than …
MDMA-assisted therapy has been studied for several decades as a potential approach for treating post-traumatic stress disorder under controlled clinical conditions. Unlike recreational use, MDMA research occurs within structured therapeutic frameworks that include medical screening, professional supervision, and standardized protocols. Researchers emphasize that this work follows the same regulatory standards applied to all investigational therapies …
Ibogaine is a naturally occurring psychoactive compound derived from the root bark of the African shrub Tabernanthe iboga. It has attracted scientific interest for its complex effects on the brain, particularly in relation to addiction and withdrawal. However, researchers emphasize that ibogaine presents unique challenges compared to other compounds currently under psychedelic research (National Institutes of …
Breakthrough Therapy designation is a regulatory status granted by the U.S. Food and Drug Administration to investigational drugs that show early evidence of potential improvement over existing treatments for serious or life-threatening conditions. In psychedelic research, this designation is often misunderstood as approval or legalization, but scientists and regulators emphasize that it represents neither (U.S. …
What Breakthrough Therapy Designation Really Means Read More »
The psychedelic research pipeline refers to the structured process through which compounds are studied, tested, and evaluated for safety and potential therapeutic use. This process follows established scientific and regulatory standards used for all investigational substances in the United States. Researchers emphasize that progress through the pipeline is gradual and evidence-driven, often taking many years …
Scientific interest in psilocybin microdosing has increased, but researchers emphasize that safety data remains limited. Most existing studies were not designed to assess long-term exposure, repeated use, or cumulative effects. As a result, public health agencies caution that conclusions about safety should be considered preliminary (National Institute on Drug Abuse). One of the primary unknowns …
Microdosing Safety, Frequency, and What Remains Unknown Read More »
Brain imaging has become a central tool in modern psychedelic research, but its application to microdosing remains limited. While full-dose psilocybin studies frequently use imaging techniques to observe changes in brain networks, researchers caution that microdosing presents unique measurement challenges due to the subtle nature of the doses involved (National Institutes of Health). Most neuroimaging …
One of the most consistent findings in microdosing research is the powerful role of expectation. Scientists have long known that belief alone can influence how people perceive mood, focus, and well-being. In microdosing studies, this effect appears especially strong, making it difficult to separate true pharmacological effects from placebo responses (National Institutes of Health). Placebo …
Microdosing refers to the practice of taking very small amounts of a substance at doses intended to avoid noticeable perceptual effects. In recent years, microdosing psilocybin has gained attention in public discourse, but scientific research on the topic remains limited and mixed. Researchers emphasize that interest has grown faster than high-quality evidence (National Institutes of …
